Moreover, since tumour molecular profiling supported the IL-3Rα expression in human samples and its potential role in driving tumour aggressiveness in vivo, we proved that its activation drives tumour progression; thus, investigating IL-3Rα as a potential therapeutic target presents a valuable challenge. This evidence concerns the gene IL3RA and neoplasm.